Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of 9-valent HPV vaccine in Japanese boys and girls aged 9 to 15 years
jRCT2031210080Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (3 arms), sponsored by Merck & Co. Primary endpoints: Seroconversion percentage for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, Participants with at least 1 solicited injection-site adverse event and 3 more. Started May 2021; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on jRCT2031210080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210080.